Inogen, Inc. is a medical technology company focused on respiratory health, developing, manufacturing, and marketing portable oxygen concentrators (POCs) for long-term oxygen therapy. Its core products include the Inogen One and Inogen Rove POC systems, which provide supplemental oxygen using battery power or standard outlets to enhance patient mobility. The company also offers the Simeox airway clearance device for patients with bronchiectasis, cystic fibrosis, or COPD, and distributes the Inogen Voxi 5 stationary oxygen concentrator and Aurora CPAP masks for obstructive sleep apnea. Inogen serves patients with chronic respiratory conditions and home medical equipment providers in the United States, Europe, and select Asia-Pacific markets. Incorporated in 2001, the company expanded its portfolio through the acquisitions of New Aera and Physio-Assist. In 2025, Inogen entered a strategic collaboration with Yuwell to distribute respiratory products in the U.S. and Asia-Pacific regions and to accelerate market entry in China.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage inogen.com
Sector Healthcare IR page investor.inogen.com
Tags
portable oxygen concentrators, respiratory health, oxygen therapy, airway clearance, cpap therapy, chronic obstructive pulmonary disease, bronchiectasis, home medical equipment, Inogen One, Inogen Rove, Simeox, Inogen Voxi 5, Aurora, Inogen Europe B.V., New Aera, Physio-Assist, PhysioAssist GmbH, Yuwell
Press page —

Metrics

Valuation  
Market cap $ 138.057M
Market cap (USD) $ 138.057M
P/E -6.13
PEG —
P/BV 0.88
P/S 0.46
P/OCF -15.08
P/FCF -12.18
Dividend yield —
Turnover / mcap —
Returns  
ROE -12.4%
ROI -22.1%
ROIC -22.0%
Profit margin -7.7%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 25
Quality score -22.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 295.304M 278.756M 251.607M 320.549M 311.73M 280.189M 340.546M 336.015M 249.438M 202.829M 159.005M 112.537M 75.443M
Net profit -22.747M -35.888M -102.449M -83.772M -6.333M -5.829M 20.95M 51.845M 21.002M 20.519M 11.585M 6.826M 25.435M
Free cash flow -13.739M 2.554M -8.452M -40.869M 18.151M 32.628M 37.45M 51.934M 57.58M 29.316M 35.953M 14.146M 10.437M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 6.72 9.17 5.49 19.71 34 44.68 68.33 124.17 119.08 67.17 40.09 31.37 —
Price performance 12m -0.27 0.67 -0.72 -0.42 -0.24 -0.35 -0.45 0.04 0.77 0.68 0.28 — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 30.8M 31.4M 37M 34.3M 29.7M 24.5M 62.7M 42.2M 29.6M 38.9M
↳ YoY growth +55.1% +2.0% +17.8% -7.3% -13.4% -17.7% +156.5% -32.7% -30.0% +31.5%
↳ 5y CAGR +29.3% +12.1% +8.4% -4.5% +14.8% +2.7% -2.9% +5.5%
Lease liabilities (USD) — — 6.42M 6.72M 10M 26.7M 23.3M 21.9M 19.4M 17.5M
Cash and deposits (USD) 92.9M 143M 197M 198M 212M 236M 187M 125M 114M 104M
Intangible assets (USD) 241,000 4.72M 3.76M 77.5M 68.8M 60.1M 177,000 34.6M 30.5M 30.8M
Right-of-use assets (USD) — — 6.42M 5.86M 8.83M 24.9M 21.7M 20.3M 18.3M 16.5M
Cash flow detail
Operating cash flow (USD) 31M 60.5M 60M 40.6M 37M 23.6M -37.5M -3.23M 5.91M -11.2M
Purchases of property, plant and equipment (USD) -1.72M -2.91M -8.04M -3.14M -4.39M -5.48M -3.34M -5.22M -3.36M -2.52M
Purchases of intangible assets (USD) -113,000 -3.32M -350,000 -254,000 -255,000 -132,000 — -494,000 -2.09M —
Change in receivables (cash effect) (USD) -32.7M -18.3M -26M -16.7M -8.18M -6.13M -51.3M 10.1M -5.19M -14.6M
Change in inventories (cash effect) (USD) -7.46M -5.89M -9.97M -10.3M 7.59M -10.8M -5.6M 7.88M -3.54M -3.21M
Change in payables (cash effect) (USD) -86,000 7.44M 6.36M 3.2M -5.83M -6.48M 6.76M -9.18M -3.41M 5.6M
Interest paid (cash effect) (USD) -10,000 — — — — — — — — —
Income taxes paid (cash effect) (USD) 447,000 -1.27M -1.65M -239,000 713,000 -1.54M -499,000 703,000 -375,000 -320,000
Share-based compensation (USD) 7.29M 9.64M 12.8M 9.13M 8.2M 10.9M 12.3M 7.43M 7.4M 8.01M
Operating cash flow before change in receivables (USD) 63.8M 78.8M 85.9M 57.3M 45.2M 29.8M 13.8M -13.4M 11.1M 3.41M
Free cash flow (OCF - PPE - intangibles) (USD) 29.2M 54.3M 51.6M 37.2M 32.4M 18M -40.9M -8.95M 464,000 -13.7M
Income detail
Research and development expense (USD) 5.11M 5.31M 7.03M 9.4M 14.1M 16.6M 21.9M 20.8M 21.6M 19.4M
↳ 5y CAGR +23.4% +18.6% +24.0% +25.9% +27.5% +26.5% +32.8% +24.3% +18.1% +6.6%
Total comprehensive income (USD) 20.5M 21.3M 52.3M 20.1M -5.27M -5.34M -85.5M -101M -38.6M -17M
Comprehensive income to owners (USD) 20.5M 21.3M 52.3M 20.1M -5.27M -5.34M -85.5M -101M -38.6M -17M
Reported Feb 28, 2017 Feb 27, 2018 May 7, 2019 Feb 25, 2020 Feb 24, 2021 Feb 24, 2022 Feb 24, 2023 Mar 1, 2024 Feb 28, 2025 Feb 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Inogen Announces Leadership Transition Bull 3 Bear 0 M&A

Download as PDF November 05, 2026

Chief Operating Officer Andy Reding Appointed President and Chief Executive Officer

BEVERLY, Mass.--(BUSINESS WIRE)-- Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that its Board of Directors has appointed Andy Reding, the Company’s Chief Operating Officer, as President and Chief Executive Officer and a member of the Board of Directors. Mr. Reding succeeds Kevin Smith.

Mr. Reding has more than 30 years of experience in medical technology, including commercial operations, product development, respiratory care, and healthcare reimbursement. Prior to joining Inogen as COO in July 2026, he served as Chief Commercial Officer of Viant Medical, where he led the company’s global commercial organization and teams supporting complex medical-device design and manufacturing programs. Before that, he served as Vice President and General Manager of Hillrom Respiratory Health from 2015 to 2020, leading the business across sales, marketing, customer service, and research and development.

“With an expanded range of respiratory therapies and a growing international presence, Inogen has a significant opportunity to build on its strengths and drive sustainable, profitable growth,” said Elizabeth Mora, Chairperson of Inogen’s Board of Directors. “At the same time, we must do more to improve performance to capture the opportunity in front of us, and the Board has determined that now is the right time to make this transition. Andy brings proven experience in building high-performing teams and scaling complex medtech businesses like ours. He played a central role in the Rotech divestiture announced in September, which we expect will advance our shift toward a more streamlined commercial model. We believe his expertise in respiratory care and medical technology, together with his background leading commercial and operational organizations, makes him ideally positioned to lead Inogen through our next phase of growth.”

“I joined Inogen in July because I believe in the Company’s mission of improving the quality of life for people living with chronic respiratory conditions,” said Mr. Reding. “Over the last few months, my excitement about Inogen and our opportunities grew. I came to better understand and appreciate the strength of our team, our differentiated product portfolio, and our deep customer relationships. I also see significant opportunities for us to sharpen our focus, strengthen execution, and expand access to our innovative respiratory solutions, and I look forward to working with the team as we focus on creating value for customers and shareholders.”

Ms. Mora added, “On behalf of the Board, we are grateful for Kevin’s leadership and for the role he has played in helping broaden and expand Inogen’s reach.”

Third Quarter 2026 Financial Results

Today, the Company will separately announce financial results for the third quarter ended September 30, 2026, and host a conference call with investors and analysts at 5:00 p.m. ET.

About Andy Reding

Andy Reding joined Inogen as the Chief Operating Officer in July 2026. Prior to that, he served as Chief Commercial Officer of Viant Medical, where for more than six years he led teams supporting complex medical-device design and manufacturing programs. Mr. Reding has extensive respiratory care experience as he served as Vice President and General Manager of Hillrom Respiratory Health, where he led sales, marketing, customer service, research and development, reimbursement, and third-party billing. During his tenure, his team expanded the sales force, developed new products, and successfully navigated FDA and CMS requirements to bring innovative products to market. Mr. Reding holds a Master of Business Administration from the University of South Carolina and a bachelor’s degree from Marquette University.

About Inogen

Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products widely available, allowing patients the chance to manage the impact of their disease.

Download as PDF November 05, 2026

Related Documents

Audio

Earnings Webcast

Supplemental Financials

PDF

Transcript

PDF

Board of Directors appoints Andy Reding as President and Chief Executive Officer

Company initiates a $20 million cost reduction program to accelerate profitability

Completes U.S. oxygen rental divestiture to simplify commercial model

BEVERLY, Mass.--(BUSINESS WIRE)-- Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September 30, 2026.

“I am excited to lead Inogen at an important inflection in the Company’s evolution,” said Andy Reding, President and Chief Executive Officer. “We have a strong foundation, including a talented team, a differentiated portfolio of respiratory solutions, and deep customer relationships. At the same time, we have meaningful opportunities to sharpen our focus, strengthen execution, and improve commercial and operational performance. We remain focused on building a simpler, more focused company that can deliver sustainable, profitable growth and create long-term value for our shareholders.”

Recent Business Highlights

  • Announced the appointment of Andy Reding as President and Chief Executive Officer and member of the Board of Directors
  • Completed the divestiture of the U.S. oxygen rental business on November 2, 2026, for total estimated cash consideration of up to $24.8 million, sharpening the Company’s commercial focus and establishing a long-term supply agreement that expands patient access to Inogen’s oxygen concentrators through a national distribution network
  • Initiated a cost reduction program beginning in the fourth quarter of 2026 that is expected to generate approximately $20 million of annualized savings by the end of 2027
  • Delivered GAAP total revenue from continuing operations of $77.2 million in the third quarter of 2026, reflecting the divestiture of the U.S. oxygen rental business
  • Reported GAAP loss from continuing operations of $14.8 million in the third quarter of 2026 compared to $3.6 million in the prior-year period. Adjusted loss from continuing operations was $0.4 million in the third quarter of 2026 compared to adjusted earnings of $1.2 million in the prior-year period
  • Increased the Company’s existing share repurchase program authorization by $15 million bringing the total authorization to $45 million and further enhancing Inogen’s ability to return capital to shareholders
  • Announced the Board of Directors’ intention to submit proposals at the 2027 Annual Meeting of Stockholders to declassify the Board, with all directors to be elected annually, and eliminating supermajority voting requirements in the Company’s Certificate of Incorporation and Bylaws

Third Quarter 2026 Financial Results

GAAP total revenue in the third quarter of 2026 was $77.2 million, a decrease of 2.4% from $79.1 million in the prior-year period, or a decrease of 3.2% on a constant currency basis. Revenue growth in the U.S. of 3.8%, was driven by demand for our portable oxygen concentrators, or POCs, and new products and was partially offset by capital softness in international markets.

GAAP gross margin was 44.1% in the third quarter of 2026 compared to 45.7% in the prior-year period. Adjusted gross margin was 44.2% in the third quarter of 2026 compared to 45.9% in the prior-year period due to a change in mix driven by lower international sales which more than offset continued cost of revenue improvements.

GAAP loss from continuing operations was $14.8 million in the third quarter of 2026 compared to $3.6 million in the prior-year period. Adjusted loss from continuing operations was $0.4 million in the third quarter of 2026 compared to adjusted earnings from continuing operations of $1.2 million in the prior-year period.

GAAP net loss per diluted share from continuing operations of $0.56 compared to $0.13 in the prior-year period. Adjusted net loss per diluted share from continuing operations was $0.02 in the third quarter of 2026 compared to adjusted net earnings per diluted share from continuing operations of $0.04 in the prior-year period.

Cash, cash equivalents, marketable securities, and restricted cash were $97.7 million as of September 30, 2026, with no debt outstanding. The Company repurchased 1,786,850 shares of common stock for $11.2 million year-to-date under the share repurchase program announced in the first quarter of 2026.

With the divestiture of the rental business, the Company has classified the results of that business as discontinued operations for all periods presented. Unless otherwise noted, financial results, non-GAAP measures, and guidance in this press release reflect continuing operations only, and prior period amounts have been recast to conform to the current presentation. Reconciliations of gross margin, operating expense, operating loss, net loss / earnings, and net loss / earnings per diluted share for the three and nine months ended September 30, 2026 and 2025 are in the financial schedules that are a part of this press release. An explanation of these non-GAAP financial measures is also included below under the heading “Reconciliation of U.S. GAAP to Non-GAAP Financial Measures.”

Fourth Quarter and Full Year 2026 Financial Outlook

Due to the divestiture of the rental business, Inogen is now providing financial guidance from continuing operations. Inogen now expects fourth quarter 2026 revenue from continuing operations in the range of $65 million and $68 million.

For the full year 2026, Inogen now expects revenue from continuing operations in the range of $298 million and $301 million.

The Company expects an adjusted loss from continuing operations of $7 million to $8 million for full-year 2026.

The Company has not provided a reconciliation of forward-looking adjusted net loss to the most directly comparable GAAP measure because certain items that impact net loss are uncertain or outside the Company's control and cannot be reasonably predicted without unreasonable effort.

Corporate Governance Update

Inogen’s Board of Directors intends to submit proposals to stockholders at the Company’s 2027 Annual Meeting of Stockholders to (a) amend the Company’s Certificate of Incorporation to declassify the Board so that all directors are elected annually, and (b) eliminate the supermajority voting requirements in the Company’s Certificate of Incorporation and Bylaws. At the 2026 Annual Meeting on June 5, 2026, more than 99% of the votes cast for or against the Board’s declassification proposal were in favor. However, the proposal did not reach the affirmative vote of 66 2/3% of outstanding shares that the Company’s Certificate of Incorporation requires.

Quarterly Conference Call Information

On November 5, 2026, the Company will host a conference call at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time.

Individuals interested in listening to the conference call may do so by dialing:

U.S. domestic callers (877) 841-3961
Non-U.S. callers (201) 689-8589

Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Investor Relations website. This webcast will also be archived on the website for six months.

A replay of the call will be available approximately three hours after the live webcast ends and will be accessible through November 12, 2026. To access the replay, dial (877) 660-6853 or (201) 612-7415 and reference Conference ID: 13761255.

Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/ , as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Inogen

Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products widely available, allowing patients the chance to manage the impact of their disease.

Download as PDF October 15, 2026

BEVERLY, Mass.--(BUSINESS WIRE)-- Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report third quarter 2026 financial results after the market closes on Thursday, November 5, 2026. On the same day, the Company will host a conference call at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time.

Individuals interested in listening to the conference call may do so by dialing:

U.S. domestic callers (877) 841-3961
Non-U.S. callers (201) 689-8589

Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Investor Relations website. This webcast will also be archived on the website for 6 months.

A replay of the call will be available approximately three hours after the live webcast ends and will be accessible through November 12, 2026. To access the replay, dial (877) 660-6853 or (201) 612-7415 and reference Conference ID: 13762851.

Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/ , as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Inogen

Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products widely available, allowing patients the chance to manage the impact of their disease.

Prompts

Inogen, Inc (ticker INGN), listed in United States.

ETFs Holding Inogen, Inc

ETF Weight in ETF Shares Market value As of
CVAR 0.40% 26,722 $ 172.357K Jul 31, 2026
FSCC 0.12% 81,332 $ 436.753K Aug 31, 2026
SCDS 0.08% 1,211 $ 6,884.54 Nov 17, 2026
FEAC 0.05% 1,951 $ 12.584K Jun 30, 2026
AVSC 0.01% 48,644 $ 273.866K Nov 16, 2026
DFAS 0.00% 156,392 $ 878.923K Nov 12, 2026
DXUV 0.00% 12,893 $ 72.459K Nov 12, 2026
DFSU 0.00% 3,200 $ 17.984K Nov 12, 2026
DCOR 0.00% 28,710 $ 161.35K Nov 12, 2026
DFAC 0.00% 41,509 $ 233.281K Nov 12, 2026
DFUS 0.00% 3,192 $ 17.939K Nov 12, 2026
AVUS 0.00% 2,676 $ 15.066K Nov 16, 2026
AVSU 0.00% 66 $ 371.58 Nov 16, 2026